IMMU earnings call for the period ending September 30, 2019.
News & Analysis: Immunomedics
It's highly likely that Immunomedics' billion-dollar drug will finally be approved by the FDA.
Major binary events like late-stage clinical trial results or drug approvals offer high-risk, high-reward opportunities for those who can stomach the uncertainty.
Unfortunately, there were more of the latter.
The market isn't pleased with its latest clinical update.
Doctors, researchers, and pharmaceutical experts will converge upon Barcelona to share the latest results in cancer research. Here is a run-down on three to watch.
IMMU earnings call for the period ending June 30, 2019.
IMMU earnings call for the period ending December 31, 2018.
These stocks missed out on the market rally.
The FDA sent the biotech back to the drawing board.